Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2013

01-04-2013 | Research Article

Effect of GSTM1 polymorphism on risks of basal cell carcinoma and squamous cell carcinoma: a meta-analysis

Authors: Hao Peng, Quanyong He, Jie Zhu, Cheng Peng

Published in: Tumor Biology | Issue 2/2013

Login to get access

Abstract

Glutathione S-transferases are important enzymes in the detoxification of a wide range of reactive oxygen species produced during melanin synthesis and oxidative stress processes. Glutathione S-transferase M1 (GSTM1) null genotype may be a candidate genetic polymorphism with a role in susceptibility to skin cancer such as basal and squamous cell carcinomas. We conducted a systematic review and meta-analysis to define the effect of GSTM1 null polymorphism on skin cancer risk. We searched the PubMed, Embase, and Web of Science databases to identify published case–control studies investigating the association between GSTM1 null genotype and skin cancer risk. Between-study heterogeneity was assessed using the I 2 statistic. Odds ratios (OR) with corresponding 95 % confidence intervals (95 % CI) from individual studies were pooled using fixed and random effects models. Nineteen case–control studies (4,275 cases and 4,255 controls) were considered eligible and included in the meta-analysis, and 11 of which were on basal cell carcinoma; ten, on melanoma, and seven, on squamous cell carcinoma. Overall, the GSTT1 null genotype was not associated with the risk of skin cancer (OR, 1.01; 95 % CI 0.93–1.11; P = 0.76). Subgroup analysis by histological types showed that GSTT1 null genotype was not associated with risks of basal cell carcinoma (OR, 1.06; 95 % CI 0.92–1.21; P = 0.42), squamous cell carcinoma (OR, 0.97; 95 % CI 0.76–1.24; P = 0.80), and cutaneous malignant melanoma (OR, 1.00; 95 % CI 0.88–1.14; P = 0.60). Therefore, this meta-analysis suggests that GSTM1 null polymorphism is not associated with risks of basal and squamous cell carcinomas.
Literature
1.
Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma in the era of molecular profiling. Lancet. 2009;374:362–5.PubMedCrossRef
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
3.
4.
Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365:687–701.PubMed
5.
6.
Lin JS, Eder M, Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;154:190–201.PubMed
7.
Capell BC, Tlougan BE, Orlow SJ. From the rarest to the most common: insights from progeroid syndromes into skin cancer and aging. J Invest Dermatol. 2009;129:2340–50.PubMedCrossRef
8.
Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients—where do we stand today? Am J Transplant. 2008;8:2192–8.PubMedCrossRef
9.
Autier P, Boyle P. Artificial ultraviolet sources and skin cancers: rationale for restricting access to sunbed use before 18 years of age. Nat Clin Pract Oncol. 2008;5:178–9.PubMedCrossRef
10.
Kemp CJ. Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin Canc Biol. 2005;15:460–73.CrossRef
11.
Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA. 2008;299:2423–36.PubMedCrossRef
12.
Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51–88.PubMedCrossRef
13.
Strange RC, Spiteri MA, Ramachandran S, Fryer AA. Glutathione-S-transferase family of enzymes. Mutat Res. 2001;482:21–6.PubMedCrossRef
14.
Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology. 2000;61:154–66.PubMedCrossRef
15.
Pearson WR, Vorachek WR, Xu SJ, Berger R, Hart I, Vannais D, Patterson D. Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. Am J Hum Genet. 1993;53:220–33.PubMed
16.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
17.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Canc Inst. 1959;22:719–48.
18.
19.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef
20.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
21.
Ramachandran S, Lear JT, Ramsay H, Smith AG, Bowers B, Hutchinson PE, Jones PW, Fryer AA, Strange RC. Presentation with multiple cutaneous basal cell carcinomas: association of glutathione S-transferase and cytochrome p450 genotypes with clinical phenotype. Cancer Epidemiol Biomarkers Prev. 1999;8:61–7.PubMed
22.
Clairmont A, Sies H, Ramachandran S, Lear JT, Smith AG, Bowers B, Jones PW, Fryer AA, Strange RC. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis. 1999;20:1235–40.PubMedCrossRef
23.
Lear JT, Smith AG, Heagerty AH, Bowers B, Jones PW, Gilford J, Alldersea J, Strange RC, Fryer AA. Truncal site and detoxifying enzyme polymorphisms significantly reduce time to presentation of further primary cutaneous basal cell carcinoma. Carcinogenesis. 1997;18:1499–503.PubMedCrossRef
24.
Lear JT, Smith AG, Bowers B, Heagearty AH, Jones PW, Gilford J, Alldersea J, Strange RC, Fryer AA. Truncal tumor site is associated with high risk of multiple basal cell carcinoma and is influenced by glutathione S-transferase, GSTT1, and cytochrome P450, CYP1A1 genotypes, and their interaction. J Invest Dermatol. 1997;108:519–22.PubMedCrossRef
25.
Yang X, Pfeiffer RM, Goldstein AM. Influence of glutathione-S-transferase (GSTM1, GSTP1, GSTT1) and cytochrome p450 (CYP1A1, CYP2D6) polymorphisms on numbers of basal cell carcinomas (BCCs) in families with the naevoid basal cell carcinoma syndrome. J Med Genet. 2006;43:e16.CrossRef
26.
Ramachandran S, Fryer AA, Strange RC. Genetic factors determining cutaneous basal cell carcinoma phenotype. Med Pediatr Oncol. 2001;36:559–63.PubMedCrossRef
27.
Ramachandran S, Fryer AA, Smith AG, Lear JT, Bowers B, Hartland AJ, Whiteside JR, Jones PW, Strange RC. Basal cell carcinomas: association of allelic variants with a high-risk subgroup of patients with the multiple presentation phenotype. Pharmacogenetics. 2001;11:247–54.PubMedCrossRef
28.
Ramachandran S, Hoban PR, Ichii-Jones F, Pleasants L, Ali-Osman F, Lear JT, Smith AG, Bowers B, Jones PW, Fryer AA, Strange RC. Glutathione S-transferase GSTP1 and cyclin D1 genotypes: association with numbers of basal cell carcinomas in a patient subgroup at high-risk of multiple tumours. Pharmacogenetics. 2000;10:545–56.PubMedCrossRef
29.
McCarty KM, Ryan L, Houseman EA, Williams PL, Miller DP, Quamruzzaman Q, Rahman M, Mahiuddin G, Smith T, Gonzalez E, Su L, Christiani DC. A case-control study of GST polymorphisms and arsenic related skin lesions. Environ Health. 2007;6:5.PubMedCrossRef
30.
Chaudru V, Lo MT, Lesueur F, Marian C, Mohamdi H, Laud K, Barrois M, Chompret A, Avril MF, Demenais F, Bressac-de Paillerets B. Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes. Fam Cancer. 2009;8:371–7.PubMedCrossRef
31.
Bu H, Rosdahl I, Holmdahl-Kallen K, Sun XF, Zhang H. Significance of glutathione S-transferases M1, T1 and P1 polymorphisms in swedish melanoma patients. Oncol Rep. 2007;17:859–64.PubMed
32.
Chiyomaru K, Nagano T, Nishigori C. Polymorphisms of glutathione S-transferase in skin cancers in a Japanese population. Kobe J Med Sci. 2011;57:E11–6.PubMed
33.
Dolzan V, Rudolf Z, Breskvar K. Genetic susceptibility to environmental carcinogenesis in Slovenian melanoma patients. Acta Dermatovenerol Alp Panonica Adriat. 2006;15:69–78.PubMed
34.
Fortes C, Mastroeni S, Boffetta P, Innocenzi L, Antonelli G, Giovinazzo R, Anzidei P, Melchi F, DA S, Pasquini P, Venanzetti F. Polymorphisms of GSTM1 and GSTT1, sun exposure and the risk of melanoma: a case-control study. Acta Derm Venereol. 2011;91:284–9.PubMedCrossRef
35.
Fryer AA, Ramsay HM, Lovatt TJ, Jones PW, Hawley CM, Nicol DL, Strange RC, Harden PN. Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients. Carcinogenesis. 2005;26:185–91.PubMedCrossRef
36.
Heagerty A, Smith A, English J, Lear J, Perkins W, Bowers B, Jones P, Gilford J, Alldersea J, Fryer A, Strange RC. Susceptibility to multiple cutaneous basal cell carcinomas: significant interactions between glutathione S-transferase gstm1 genotypes, skin type and male gender. Br J Cancer. 1996;73:44–8.PubMedCrossRef
37.
Heagerty AH, Fitzgerald D, Smith A, Bowers B, Jones P, Fryer AA, Zhao L, Alldersea J, Strange RC. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet. 1994;343:266–8.PubMedCrossRef
38.
Ibarrola-Villava M, Martin-Gonzalez M, Lazaro P, Pizarro A, Lluch A, Ribas G. Role of glutathione S-transferases in melanoma susceptibility: association with GSTP1 rs1695 polymorphism. Br J Dermatol. 2012;166:1176–83.PubMedCrossRef
39.
Kanetsky PA, Holmes R, Walker A, Najarian D, Swoyer J, Guerry D, Halpern A, Rebbeck TR. Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Canc Epidemiol Biomarkers Prev. 2001;10:509–13.
40.
Lafuente A, Molina R, Palou J, Castel T, Moral A, Trias M. Phenotype of glutathione S-transferase mu (GSTM1) and susceptibility to malignant melanoma. MMM group. Multidisciplinary Malignant Melanoma Group. Br J Cancer. 1995;72:324–6.PubMedCrossRef
41.
Leite JL, Morari EC, Granja F, Campos GM, Guilhen AC, Ward LS. Influence of the glutathione S-transferase gene polymorphisms on the susceptibility to basal cell skin carcinoma. Rev Med Chil. 2007;135:301–6.PubMed
42.
Lira MG, Provezza L, Malerba G, Naldi L, Remuzzi G, Boschiero L, Forni A, Rugiu C, Piaserico S, Alaibac M, Turco A, Girolomoni G, Tessari G. Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. Exp Dermatol. 2006;15:958–65.PubMedCrossRef
43.
Marshall SE, Bordea C, Haldar NA, Mullighan CG, Wojnarowska F, Morris PJ, Welsh KI. Glutathione S-transferase polymorphisms and skin cancer after renal transplantation. Kidney Int. 2000;58:2186–93.PubMedCrossRef
44.
Mertens AC, Mitby PA, Radloff G, Jones IM, Perentesis J, Kiffmeyer WR, Neglia JP, Meadows A, Potter JD, Friedman D, Yasui Y, Robison LL, Davies SM. XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. Cancer. 2004;101:1463–72.PubMedCrossRef
45.
Mossner R, Anders N, Konig IR, Kruger U, Schmidt D, Berking C, Ziegler A, Brockmoller J, Kaiser R, Volkenandt M, Westphal GA, Reich K. Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Arch Dermatol Res. 2007;298:371–9.PubMedCrossRef
46.
Ramsay HM, Harden PN, Reece S, Smith AG, Jones PW, Strange RC, Fryer AA. Polymorphisms in glutathione S-transferases are associated with altered risk of nonmelanoma skin cancer in renal transplant recipients: a preliminary analysis. J Invest Dermatol. 2001;117:251–5.PubMedCrossRef
47.
Shanley SM, Chenevix-Trench G, Palmer J, Hayward N. Glutathione S-transferase GSTM1 null genotype is not overrepresented in australian patients with nevoid basal cell carcinoma syndrome or sporadic melanoma. Carcinogenesis. 1995;16:2003–4.PubMedCrossRef
48.
Xie F, Zhang ZW, Li Z, Yu H, Li L, Li H. Relationship between the deletion of GSTM1, GSTT1 genes and susceptibility to malignant of nail matrix nnevus. Zhong Hua Shi Yan Wai Ke Za Zhi. 2011;27:1279–31.
49.
Yengi L, Inskip A, Gilford J, Alldersea J, Bailey L, Smith A, Lear JT, Heagerty AH, Bowers B, Hand P, Hayes JD, Jones PW, Strange RC, Fryer AA. Polymorphism at the glutathione S-transferase locus GSTM3: interactions with cytochrome p450 and glutathione S-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma. Cancer Res. 1996;56:1974–7.PubMed
50.
Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol. 2007;4:462–9.PubMedCrossRef
51.
Diaz-Lagares A, Alegre E, Arroyo A, Gonzalez-Cao M, Zudaire ME, Viteri S, Martin-Algarra S, Gonzalez A. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol. 2011;32:1155–61.PubMedCrossRef
52.
Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, Zhang D, Zhou W. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53:508–18.PubMedCrossRef
53.
Gervasini G, San Jose C, Carrillo JA, Benitez J, Cabanillas A. GST polymorphisms interact with dietary factors to modulate lung cancer risk: study in a high-incidence area. Nutr Cancer. 2010;62:750–8.PubMedCrossRef
54.
Lourenco GJ, Silva EF, Rinck-Junior JA, Chone CT, Lima CS. CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma. Tumour Biol. 2011;32:1209–15.PubMedCrossRef
Metadata
Title
Effect of GSTM1 polymorphism on risks of basal cell carcinoma and squamous cell carcinoma: a meta-analysis
Authors
Hao Peng
Quanyong He
Jie Zhu
Cheng Peng
Publication date
01-04-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0595-9

Other articles of this Issue 2/2013

Tumor Biology 2/2013 Go to the issue

Research Article

Effects of Kruppel-like factor 6 on osteosarcoma cell biological behavior

Research Article

Association between the NBS1 Glu185Gln polymorphism and breast cancer risk: a meta-analysis

Research Article

Beclin 1 expression is an independent prognostic factor for gastric carcinomas

Research Article

Molecular diagnosis and prognostic significance of lymph node micrometastasis in patients with histologically node-negative non-small cell lung cancer

Research Article

Abnormal hypermethylation and clinicopathological significance of Axin gene in lung cancer

Research Article

Involvement of PKCα activation in TF/VIIa/PAR2-induced proliferation, migration, and survival of colon cancer cell SW620
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits